Higher SII Levels Associated with Increased Atrial Fibrillation Recurrence Risk After Ablation: Study Shows

China: A recent study published in Heart Rhythm has highlighted the role of the systemic immune-inflammation index (SII) as a significant predictor of atrial fibrillation (AF) recurrence following catheter ablation in patients with hypertension. The findings indicate that the SII strongly predicted AF recurrence following catheter ablation in hypertensive patients.
"AF recurrence was observed in 17.94% of cases, with a significant increase in risk beyond a threshold of 457.41 ×10⁹/L. SII demonstrated superior predictive accuracy compared to C-reactive protein and high-sensitivity C-reactive protein (AUC: 0.688 vs. 0.510 and 0.542), reinforcing its potential role in risk stratification," the researchers reported.
Atrial fibrillation remains a common and challenging cardiac arrhythmia, particularly in hypertensive patients, who face a higher risk of recurrence even after catheter ablation. Inflammation is increasingly recognized as a key factor in AF pathophysiology. SII—a composite marker derived from platelet, neutrophil, and lymphocyte counts—has emerged as a promising indicator of systemic inflammation.
Against the above background, Qiming Liu, Department of Cardiology, The Second Xiangya Hospital, Central South University, Changsha City, Hunan Province, People’s Republic of China, and colleagues aimed to assess the predictive significance of the systemic immune-inflammation index for AF recurrence following catheter ablation in hypertensive patients.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.